Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment

High-dose isoniazid is recommended to treat multidrug-resistant tuberculosis (MDR TB). Among 958 MDR TB isolates identified in France during 2008-2022, 93.1% exhibited high-level isoniazid resistance, and molecular testing showed limited diagnostic accuracy in predicting resistance. Clinicians shoul...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Emerging infectious diseases Ročník 31; číslo 3; s. 633 - 636
Hlavní autoři: Gerussi, Valentina, Petersen, Tania, Bonnet, Isabelle, Aubry, Alexandra, Bachir, Marwa, Gyde, Esther, Morel, Florence, Poignon, Corentin, Rached, Brigitte, Pourcher, Valérie, Rioux, Christophe, Vallois, Dorothée, Veziris, Nicolas, Robert, Jérôme, Guglielmetti, Lorenzo
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States U.S. National Center for Infectious Diseases 01.03.2025
Centers for Disease Control and Prevention
Témata:
Accuracy
Adult
Antitubercular Agents - administration & dosage
Antitubercular Agents - therapeutic use
bacteria
Clinical trials
Dosage and administration
Drug dosages
Drug resistance
Drug Resistance, Multiple, Bacterial
Drug therapy
Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment
Female
France - epidemiology
Humans
Infectious diseases
inhA
Isoniazid
Isoniazid - administration & dosage
Isoniazid - pharmacology
Isoniazid - therapeutic use
Male
MDR TB
Microbial Sensitivity Tests
Middle Aged
Multidrug resistant organisms
Mutation
Mycobacterium tuberculosis - drug effects
Mycobacterium tuberculosis - genetics
Patient outcomes
Research Letter
respiratory infections
Toxicity
Tuberculosis
tuberculosis and other mycobacteria
Tuberculosis, Multidrug-Resistant - diagnosis
Tuberculosis, Multidrug-Resistant - drug therapy
Tuberculosis, Multidrug-Resistant - epidemiology
Tuberculosis, Multidrug-Resistant - microbiology
France
Italy
Paris France
SCR
isoniazid
bacteria
drug susceptibility testing
respiratory infections
inhA
phenotypic
mutation
genotypic
antimicrobial resistance
hepatotoxicity
tuberculosis and other mycobacteria
MDR TB
katG
ISSN:1080-6040, 1080-6059, 1080-6059
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:High-dose isoniazid is recommended to treat multidrug-resistant tuberculosis (MDR TB). Among 958 MDR TB isolates identified in France during 2008-2022, 93.1% exhibited high-level isoniazid resistance, and molecular testing showed limited diagnostic accuracy in predicting resistance. Clinicians should reconsider using high-dose isoniazid in MDR TB treatment because of suboptimal effect and toxicity concerns.
Bibliografie:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ISSN:1080-6040
1080-6059
1080-6059
DOI:10.3201/eid3103.241473